QV Dermcare

WHERE TO BUY
Brands
EN
Current location and language options: (EN)
EN
Current location and language options: (EN)
Brands

Our New QV Dermcare Eczema Daily Range

Ego's new QV Dermcare Eczema Daily range are registered therapeutic devices that became the first commercially-available moisturising wash and cream of their kind in Australia. Formulated with a blend of ceramides and moisturisers, shown to significantly improve skin issues associated with moderate eczema. Interested and want to learn more? Download the clinical paper below.

Download The Full Clinical Paper

While moisturisers and cleansers are often recommended for eczema affected skin, most are cosmetic products that are only designed for normal, healthy looking skin.

Download the full clinical paper and find out why QV Dermcare Eczema Daily range is different.

DOWNLOAD
Download The Full Clinical Paper

While moisturisers and cleansers are often recommended for eczema affected skin, most are cosmetic products that are only designed for normal, healthy looking skin.

Download the full clinical paper and find out why QV Dermcare Eczema Daily range is different.

DOWNLOAD
Our Dermcare Range

  • QV Dermcare Eczema Daily Cream With Ceramides

    QV Dermcare Eczema Daily Cream With Ceramides

    Clinically tested moisturising cream for the symptomatic relief of mild to moderate eczema1.

    VIEW PRODUCT

  • QV Dermcare Eczema Daily Wash With Ceramides

    QV Dermcare Eczema Daily Wash With Ceramides

    Soap-free body wash, clinically tested for the symptomatic relief of mild to moderate eczema1.

    VIEW PRODUCT

  • QV Dermcare Sting-Free Ointment With Ceramides

    QV Dermcare Sting-Free Ointment With Ceramides

    A Ceramide enriched sting-free ointment that helps support the skin barrier. Soothes cracked, dry skin.

    VIEW PRODUCT

Eczema Managed

line

Together we can achieve a reduction in eczema severity for your patients. Learn more about Ego’s Eczema Management Plan and tailored approach. 

VIEW PAGE
References

1. Spada F et al. Dermatol Ther 2021;34(4):e14970. (n=100) Study sponsored by Ego Pharmaceuticals Pty Ltd